# Trialix - Clinical Trial Enrichment Analysis Package

## Project Scope Document

---

## 1. Executive Summary

**Trialix** is a Python package designed to optimize clinical trial design through data-driven patient selection and biomarker identification. By analyzing historical clinical trial data, Trialix helps clinical development teams maximize trial success rates while maintaining recruitment feasibility.

**Core Value Proposition:** Transform historical clinical trial data into actionable protocol recommendations for enriched patient populations, optimal inclusion/exclusion criteria, and predictive biomarker strategies.

---

## 2. Target Audience

### Primary Users
- **Clinical Development Teams**: Protocol designers and medical monitors
- **Biostatisticians**: Trial statisticians and data scientists in pharmaceutical/biotech
- **Regulatory Affairs Professionals**: CMC and clinical regulatory strategists
- **Clinical Operations**: Feasibility and site selection teams

### Use Cases
- Pre-IND/Pre-NDA trial design optimization
- Phase II to Phase III transition planning
- Failed trial rescue analysis (identify enrichable subpopulations)
- Competitive intelligence (analyzing public trial data)
- Regulatory submission support (enrichment strategy justification)

---

## 3. Core Functionality

### 3.1 Data Ingestion
**Input Formats:**
- CDISC Standards: SDTM (Study Data Tabulation Model), ADaM (Analysis Data Model)
- Generic Formats: CSV, Excel (.xlsx, .xls), SAS datasets (.sas7bdat, .xpt)
- Support for multi-domain CDISC data (DM, VS, LB, AE, EX, etc.)

**Data Types:**
- Patient demographics (age, sex, race, ethnicity, body metrics)
- Laboratory values (hematology, chemistry, biomarkers)
- Vital signs and clinical assessments
- Medical history and comorbidities
- Concomitant medications
- Adverse events
- Efficacy outcomes (survival, response rates, continuous endpoints)
- Protocol deviations and screen failures

### 3.2 Biomarker Discovery & Stratification
**Capabilities:**
- **Responder vs Non-Responder Analysis**: Identify biomarkers that differentiate treatment response
- **Survival Analysis**: Cox proportional hazards, Kaplan-Meier curves for time-to-event endpoints
- **Classification Models**: Logistic regression, random forests for binary outcomes
- **Statistical Testing**: t-tests, Mann-Whitney U, chi-square for biomarker associations
- **Feature Importance Ranking**: Identify top predictive biomarkers
- **Subgroup Discovery**: Automated identification of patient subsets with enhanced efficacy

**Output:**
- Ranked list of predictive biomarkers with effect sizes and p-values
- Patient stratification rules (e.g., "PD-L1 ‚â•50% shows 2.3x higher response rate")
- Forest plots and waterfall plots for subgroup effects

### 3.3 Inclusion/Exclusion Criteria Optimization
**Capabilities:**
- **Decision Tree Analysis**: Identify optimal cutpoints for continuous variables (age, BMI, lab values)
- **Constraint Optimization**: Balance trial power vs enrollment feasibility
- **Historical Comparison**: Benchmark proposed criteria against past trials
- **Screen Failure Prediction**: Estimate percentage of patients excluded by each criterion
- **Criteria Refinement**: Suggest removing non-predictive exclusions

**Output:**
- Recommended inclusion/exclusion criteria with rationale
- Trade-off analysis (power vs population size)
- Comparison tables (current criteria vs optimized criteria)

### 3.4 Enrollment & Feasibility Analysis
**Capabilities:**
- **Enrollment Rate Prediction**: Model patient accrual based on population prevalence and criteria
- **Sample Size Calculation**: Power analysis for enriched populations
- **Recruitment Timeline Estimation**: Predict trial duration based on site capacity
- **Geographic Feasibility**: Assess patient availability by region/country
- **Safety Signal Detection**: Flag historical safety concerns in target population

**Output:**
- Predicted enrollment metrics (screen failure rate, randomization rate, dropout rate)
- Sample size recommendations with statistical justification
- Recruitment risk assessment

### 3.5 Protocol Recommendations
**Capabilities:**
- **Evidence Synthesis**: Aggregate findings into protocol-ready language
- **Regulatory Alignment**: Frame enrichment strategies for FDA/EMA guidelines
- **Competitive Positioning**: Compare proposed design to similar trials
- **Risk Mitigation**: Identify potential protocol challenges

**Output:**
- Protocol synopsis with enrichment strategy
- Biomarker testing requirements (assay specifications, cutoffs)
- Statistical analysis plan (SAP) considerations

---

## 4. User Interfaces

### 4.1 Command-Line Interface (CLI)
```
trialix analyze --data trial_data.csv --outcome response --format csv
trialix biomarkers --data sdtm_folder/ --endpoint OS --format sdtm
trialix criteria --data data.csv --optimize enrollment --target-power 0.80
trialix report --analysis results.json --output protocol_brief.pdf
```

**Features:**
- Intuitive commands for common workflows
- Progress bars for long-running analyses
- Validation warnings for data quality issues
- Configuration via YAML/JSON files

### 4.2 Python API
```python
from trialix import TrialAnalyzer

analyzer = TrialAnalyzer(data_source="trial_data.csv", format="csv")
analyzer.load_data()
biomarkers = analyzer.discover_biomarkers(endpoint="response")
criteria = analyzer.optimize_criteria(target_power=0.80)
report = analyzer.generate_report(output="report.pdf")
```

**Features:**
- Fluent API for programmatic workflows
- Integration with Jupyter notebooks
- Customizable analysis parameters
- Export to pandas DataFrames for custom analysis

---

## 5. Key Analyses & Algorithms

### 5.1 Statistical Methods
- **Survival Analysis**: Cox regression, log-rank tests, restricted mean survival time (lifelines)
- **Hypothesis Testing**: Multiple comparison correction (Bonferroni, Benjamini-Hochberg)
- **Effect Size Estimation**: Hazard ratios, odds ratios, Cohen's d, confidence intervals
- **Propensity Score Matching**: Balance confounders in observational data

### 5.2 Machine Learning Models
- **Classification**: Logistic regression, random forests, gradient boosting (scikit-learn)
- **Feature Selection**: LASSO, recursive feature elimination, permutation importance
- **Clustering**: K-means for patient segmentation
- **Decision Trees**: CART for criteria optimization (interpretable rules)

### 5.3 Optimization Algorithms
- **Constraint Programming**: Optimize criteria subject to enrollment constraints
- **Multi-Objective Optimization**: Balance power, feasibility, cost
- **Sensitivity Analysis**: Test robustness of recommendations

### 5.4 Clinical Metrics
- **Power Calculations**: Sample size for enriched populations (statsmodels, scipy)
- **Number Needed to Screen (NNS)**: Recruitment efficiency metric
- **Positive Predictive Value (PPV)**: Biomarker accuracy for enrichment
- **Incremental Cost-Effectiveness**: Budget impact of enrichment

---

## 6. Output & Reporting

### 6.1 Visualization
- **Biomarker Plots**: Forest plots, volcano plots, Kaplan-Meier curves, ROC curves
- **Criteria Analysis**: Decision trees, waterfall charts, enrollment funnels
- **Patient Segmentation**: Scatter plots, heatmaps, dendrograms
- **Tools**: matplotlib, seaborn, plotly (interactive)

### 6.2 Report Generation
- **PDF Reports**: Executive summaries with key findings (reportlab)
- **Word Documents**: Protocol sections ready for copy-paste (python-docx)
- **Presentations**: PowerPoint slides for stakeholder meetings (python-pptx)
- **Interactive Dashboards**: HTML reports with interactive plots (Plotly Dash - future)

### 6.3 Data Exports
- **JSON/YAML**: Analysis results for programmatic access
- **CSV/Excel**: Tables for regulatory submissions
- **R Integration**: Export to .RData for biostatisticians (rpy2 - optional)

---

## 7. Technical Requirements

### 7.1 Core Dependencies
- **Python**: 3.9+ (modern type hints, performance)
- **Data Handling**: pandas (clinical datasets), numpy (numerical computation)
- **Statistics**: scipy (hypothesis tests), statsmodels (regression, power analysis)
- **Survival Analysis**: lifelines (Cox regression, Kaplan-Meier)
- **Machine Learning**: scikit-learn (classification, feature selection)
- **Visualization**: matplotlib, seaborn (publication-quality plots)
- **Reporting**: python-docx (Word), reportlab (PDF), openpyxl (Excel)
- **CLI**: Click (command-line interface)

### 7.2 Optional Dependencies
- **CDISC Parsing**: pyreadstat (SAS .xpt), xport (transport files)
- **Advanced ML**: xgboost, lightgbm (gradient boosting)
- **Interactive Viz**: plotly (dashboards)
- **Parallel Processing**: joblib, dask (large datasets)

### 7.3 Development Tools
- **Testing**: pytest (unit tests), hypothesis (property-based testing)
- **Linting**: ruff, mypy (type checking)
- **Documentation**: Sphinx (API docs), MkDocs (user guide)
- **Packaging**: setuptools, pyproject.toml (PEP 517/518)

---

## 8. Example Datasets & Tutorials

### 8.1 Included Sample Data
- **Oncology Trial**: SDTM-formatted Phase II solid tumor study with biomarkers
- **Cardiovascular Trial**: CSV format with lab values and MACE endpoints
- **Rare Disease Trial**: Small N study demonstrating power challenges
- **Public Data**: Links to clinicaltrials.gov datasets

### 8.2 Tutorial Notebooks
1. **Quickstart**: Load CSV data, run basic biomarker analysis
2. **CDISC Workflow**: Parse SDTM domains, analyze multi-domain data
3. **Enrichment Strategy**: End-to-end trial optimization case study
4. **Advanced**: Custom analysis pipelines, parameter tuning

---

## 9. Project Boundaries

### 9.1 In Scope
‚úÖ Clinical trial data analysis and enrichment strategy development
‚úÖ Biomarker discovery and patient stratification
‚úÖ Inclusion/exclusion criteria optimization
‚úÖ Enrollment feasibility and sample size calculations
‚úÖ Protocol recommendation generation
‚úÖ Statistical and ML-based analyses
‚úÖ CLI and Python API interfaces
‚úÖ PDF/Word report generation
‚úÖ CDISC SDTM/ADaM and generic format support
‚úÖ Example datasets and tutorials

### 9.2 Out of Scope (Initial Release)
‚ùå **Database Management**: No built-in data warehousing (users provide files)
‚ùå **Real-Time Data Integration**: No EDC (Electronic Data Capture) system connectors
‚ùå **Clinical Trial Management**: No patient randomization, site management, or CTMS features
‚ùå **Regulatory Submission Software**: Not a replacement for eCTD or regulatory gateways
‚ùå **AI-Powered Drug Discovery**: Focus is trial design, not target identification
‚ùå **Cloud Deployment**: Initial release is local Python package (not SaaS)
‚ùå **Multi-Trial Meta-Analysis**: Single trial or combined dataset analysis only
‚ùå **Adaptive Trial Design**: No interim analysis or dose-finding algorithms (future)

### 9.3 Future Considerations (Post-MVP)
üîÆ Web-based dashboard (Streamlit/Dash)
üîÆ Cloud deployment (AWS/GCP) for large-scale analysis
üîÆ Real-time data connectors (Medidata Rave, Oracle InForm)
üîÆ Multi-trial meta-analysis and network analysis
üîÆ Bayesian adaptive enrichment designs
üîÆ Integration with trial simulation software (FACTS, EAST)

---

## 10. Success Criteria

### 10.1 Functional Requirements
- ‚úÖ Load CDISC SDTM and CSV clinical datasets without errors
- ‚úÖ Identify at least 3 predictive biomarkers from sample oncology dataset
- ‚úÖ Generate optimized inclusion/exclusion criteria with statistical justification
- ‚úÖ Produce sample size estimate within 10% of traditional power analysis tools
- ‚úÖ Export protocol-ready PDF report in <60 seconds for 1000-patient dataset
- ‚úÖ CLI completes common workflows in <5 commands
- ‚úÖ Python API has <10 lines of code for basic analysis

### 10.2 Performance Requirements
- Process 10,000-patient dataset in <5 minutes on standard laptop (M1/Intel i7)
- Support datasets up to 100,000 patients (with progress indicators)
- Generate publication-quality plots in <10 seconds

### 10.3 Quality Requirements
- 90%+ test coverage for core analysis modules
- Type hints for all public APIs (mypy strict mode)
- Documentation for all user-facing functions
- Zero critical security vulnerabilities (Dependabot scanning)

### 10.4 Usability Requirements
- Biostatistician can complete tutorial in <30 minutes
- Errors provide actionable guidance (e.g., "Column 'AGE' missing - expected in SDTM DM domain")
- API follows pandas/scikit-learn conventions (familiar to data scientists)

---

## 11. Licensing & Distribution

- **Package Name**: `trialix` (PyPI)
- **Installation**: `pip install trialix`
- **License**: TBD (consider MIT/Apache 2.0 for open source or proprietary for commercial)
- **Platform Support**: macOS, Linux, Windows (platform-independent Python)
- **Python Versions**: 3.9, 3.10, 3.11, 3.12 (tested via CI/CD)

---

## 12. Compliance & Validation

### 12.1 Regulatory Considerations
- **21 CFR Part 11**: Not required (analysis tool, not data capture system)
- **GDPR/HIPAA**: Users responsible for data anonymization (package operates on de-identified data)
- **FDA Guidance**: Align with enrichment strategy guidance (e.g., guidance on adaptive designs)

### 12.2 Validation Strategy
- **Algorithm Validation**: Compare results to established tools (R survival package, SAS PROC LIFETEST)
- **Clinical Validation**: Partner with biostatisticians to validate on real trial data
- **Documentation**: Maintain algorithm specifications for regulatory inspection

---

## 13. Development Roadmap (High-Level)

### Phase 1: Core Functionality (MVP)
- Data ingestion (CSV, SDTM)
- Basic biomarker analysis (univariate tests, logistic regression)
- Criteria optimization (decision trees)
- CLI and Python API skeleton
- PDF report generation

### Phase 2: Advanced Analytics
- Survival analysis (Cox regression, Kaplan-Meier)
- ML models (random forests, feature importance)
- Subgroup discovery
- Sample size calculations
- Enhanced visualizations

### Phase 3: Production Readiness
- Comprehensive testing (unit, integration, validation)
- Documentation (API reference, user guide, tutorials)
- Example datasets and notebooks
- PyPI packaging and CI/CD
- Performance optimization

### Phase 4: Ecosystem Integration
- R interoperability
- Jupyter notebook widgets
- Plugin architecture for custom analyses
- Community contributions (GitHub)

---

## 14. Key Differentiators

**vs. Generic Data Science Tools (pandas, scikit-learn):**
- Pre-built clinical trial workflows (no need to code analyses from scratch)
- CDISC-native support (understands clinical data structures)
- Protocol-ready outputs (not just analysis results)

**vs. Commercial Trial Design Software (FACTS, nQuery):**
- Open-source and programmable (customizable for specific needs)
- Data-driven enrichment (learns from historical data, not just theoretical models)
- Lower cost (pip install vs. enterprise licenses)

**vs. Clinical Data Platforms (Medidata, Veeva):**
- Focused on design optimization (not trial execution or data capture)
- Lightweight and portable (runs on laptop, no infrastructure needed)
- Retrospective analysis (historical data, not real-time monitoring)

---

## 15. Non-Functional Requirements

### 15.1 Security
- No telemetry or data transmission (fully local operation)
- Support for encrypted data files (users handle encryption)
- Dependency vulnerability scanning (GitHub Dependabot)

### 15.2 Maintainability
- Modular architecture (separate modules for ingestion, analysis, reporting)
- Plugin system for custom analyses (future)
- Versioned API (semantic versioning)

### 15.3 Scalability
- Streaming ingestion for large datasets (chunked reading)
- Parallel processing for independent analyses (joblib)
- Memory-efficient algorithms (avoid full-dataset copies)

---

## 16. Glossary

- **CDISC**: Clinical Data Interchange Standards Consortium (industry standards for clinical data)
- **SDTM**: Study Data Tabulation Model (standard for raw clinical data)
- **ADaM**: Analysis Data Model (standard for analysis-ready datasets)
- **Enrichment**: Selecting a patient subpopulation more likely to respond to treatment
- **Biomarker**: Measurable biological indicator (e.g., gene expression, protein level)
- **Screen Failure**: Patient who does not meet inclusion/exclusion criteria
- **NNS**: Number Needed to Screen (patients screened per randomized patient)
- **HR**: Hazard Ratio (survival analysis effect size)
- **OR**: Odds Ratio (logistic regression effect size)

---

## 17. Contact & Contribution

- **Maintainer**: TBD
- **Repository**: TBD (GitHub)
- **Issue Tracker**: TBD (GitHub Issues)
- **Discussions**: TBD (GitHub Discussions or Slack)
- **Contributing**: CONTRIBUTING.md (guidelines for pull requests)

---

**Document Version**: 1.0
**Last Updated**: 2025-12-03
**Status**: Draft - Awaiting Review
